PET-CT detection 11C-methionine intake can determine the level of glioma

Backgroundgliomas have been used in tumor tracing because they ingest edged11C-methionine (
11C-MET) higher than normal brain tissue11C-MET ingestion process is mainly done by sodium ion non-dependent L-type amino acid transporter, which can reflect the degree of cell proliferation and is associated with the increase of synthesis, transaminate and transmethylation of substances such as proteins and non-proteinsIn general, methionine inlow-grade gliomas in the intake of lower levels of gliomaHowever, there is a clear overlap between met intake of low-grade gliomas and high-level gliomas in PET-CT imaging, making it difficult to accurately determine the level of glioma by the degree of intakeIn the 2016 WHO revision of the colloma classification criteria, gene expression spectrum was included in the tissue pathopathic phenotypic classification, reclassification of glioma classificationThe elimination of the original Oligoastrocytoma, broken down into astrocytoma and oligoddroglioma (OD); In the gene expression spectrum, isocric acid dehydrogenase 1 (IDH1) mutation can affect the classification of glioma, and the prognosis of the IDH1 mutation is better than the idh1 wild typeIDH1 mutant gliomas were further divided into 1p/19q common lysacandoma and 1p/19q no missing astrocymaDongwoo Kim, of the Department of Nuclear Medicine at Yonsei University School of Medicine in South Korea, , performed preoperative MRI-enhanced imaging and MET PET-CT scans on 144 glioma patients, and studied different types of gliomas, especially the metidh1 mutant type and 1p/19q co-missing glioma MET intake, according to the 2016 WHO central nervous system tumor classification criteria Applying computer software (MIM Software Inc., Cleveland, OH, USA) to combine PET-CT and enhanceD MRI images, and manually tracing the highest standardized intake values for tumors (SUVmax) and average standardized intake of side normal brain tissue (SUmeanVV), the ratio of SUVmax to normal brain tissue on PET-CT was analyzed statistically The results were published online may 2019 by Eur J Nucl Med Mol Imaging. results results show that when the IDH1 mutation is considered separately, the intake of IDH1 mutant tumors (TNR-1.95) is significantly lower than that of IDH1 wild tumors (TNR-3.35, p0.0001); Figure 1 PET-CT scans of gliomas (left) are compared to the corresponding MRI-enhanced imaging (right) IDH1 mutant glioblastoma (left and right) MET TNR 1.97, IDH1 wild glioblastoma (left and bottom right) MET TNR s 3.04; the intake of MET (TNR-2.9) by the idh1 mutant glioma was higher than that of astrocyma (TNR s 1.4) (p 0.001) In IDH1 mutant astral gliomas, WHO Class II low-grade astral gliomas (TNR-1.2) have significantly lower intake of MET level series (TNR-2.05) and WHO IV There was no significant difference between the intake of MET (p 0.0001 and p 0.05) of high-grade astroid gliomas (p.0001 and p 0.05); Similarly, in the case of small-sudden gliomas, WHO level II low-level small-sudden gliomas (TNR-2.3) had significantly lower intake of MET than WHO Level III high-level small gliomas (TNR-3.30) (p0.05) (Figure 2) In all levels of astrocyma, tumors with the IDH1 mutation gene had lower meta-intake capacity than wild types Figure 2 PET-CT scans of gliomas (left) are compared to the corresponding MRI-enhanced imaging (right) IDH1 Mutant WHO CLASS II Small Protoscoid Tumor (Left, Top Right) MET TNR s 2.58; WHO Class III (Interstitial) Small Prosusal Glioma (Left, Bottom Right) MET TNR s 3.41; significantly higher than WHO II Level Less Prosusal Glioma overall, only when tumor levels were considered, MET TNR of WHO Class III high-level gliomas was met TNR s 2.90; .40 (p 0.001); threshold 2.25 for determining high and low levels of tumor (AUC s 0.852), which is more suitable for judging high and low levels of idh1 wild tumors (AUC s 0.976) it is worth noting that WHO class II less protrusive gliomas have a higher level of MET intake than WHO CLASS II star cell tumors with IDH1 mutations, but there is no statistical difference between the intake of THE IDH1 wild-type WHO III and IV star cell tumors conclusions
the authors point out that by studying the intake of MET on tumors on PET-CT, it can help to better stage tumor grading and guide treatment and evaluation of prognosis.